Global market forecast of oncologics and supportive care biosimilars 2020
This statistic displays a global market forecast for oncology products and supportive care biosimilars in 2015 and 2020. By 2020, the global market is expected to reach between 6 and 12 billion U.S. dollars.
Cancer drug market
A forecast for global oncologics and supportive care biosimilars expects that the market will reach a minimum of 6 billion U.S. dollars and a maximum of 12 billon U.S. dollars in 2020. Biosimilars used for cancer treatment and supportive care will likely enter the U.S. market in the near future. These drugs will be very similar to their branded products but differences may exist due to complexities and differences in manufacturing processes. Maintaining a rigorous safety monitoring of biosimilars will be important in tracking its effectiveness and any potential consequences.
The number of cancer drugs being developed has increased over the last few years, increasing from 399 drugs in 2005 to 981 drugs in 2012. As of 2013, Rituxan/MabThera marketed by Roche was one of the top selling oncologic pharmaceutical drugs globally, reaching a revenue of 7.78 billion U.S. dollars. Roche also produces other top cancer drugs like Avastin and Herceptin which have reached revenues of 6.75 billion U.S. dollars and 6.56 billion U.S. dollars, respectively, during this year. Rituximab primarily destroy B cells which tend to be overly produced or dysfunctional in lymphomas, leukemias, autoimmune disorders, and in transplant rejections. The U.S. patent will expire in 2015 and will likely alter the market for this drug.
Cancer drug market
A forecast for global oncologics and supportive care biosimilars expects that the market will reach a minimum of 6 billion U.S. dollars and a maximum of 12 billon U.S. dollars in 2020. Biosimilars used for cancer treatment and supportive care will likely enter the U.S. market in the near future. These drugs will be very similar to their branded products but differences may exist due to complexities and differences in manufacturing processes. Maintaining a rigorous safety monitoring of biosimilars will be important in tracking its effectiveness and any potential consequences.
The number of cancer drugs being developed has increased over the last few years, increasing from 399 drugs in 2005 to 981 drugs in 2012. As of 2013, Rituxan/MabThera marketed by Roche was one of the top selling oncologic pharmaceutical drugs globally, reaching a revenue of 7.78 billion U.S. dollars. Roche also produces other top cancer drugs like Avastin and Herceptin which have reached revenues of 6.75 billion U.S. dollars and 6.56 billion U.S. dollars, respectively, during this year. Rituximab primarily destroy B cells which tend to be overly produced or dysfunctional in lymphomas, leukemias, autoimmune disorders, and in transplant rejections. The U.S. patent will expire in 2015 and will likely alter the market for this drug.
